According to the latest Filings, Depomed, Inc. (NASDAQ:DEPO) have decreased their position in the stock by -27.88% over the past 6 months. Insiders now own 1.22% of total outstanding shares.
Depomed, Inc. (NASDAQ:DEPO) stands 11.19% away from its 50-day simple moving average and also -38.63% away from the 200-day average. Recently, the equity stands -70.80% away from the 52-week high and 46.06% from the 52-week low. The RSI (Relative Strength Index), an indicator that shows price strength by comparing upward and downward close-to-close movements is 62.17.
The consensus analysts recommendation at this point stands at 2.90 for Depomed, Inc.. This is based on a 1-5 scale where 1 indicates a Strong Buy and 5 a Strong Sell. Further, analysts have a 12 month target price of $9.25 on company shares. This is according to the analysts polled by Thomson Reuters which have recently published research reports on the firm.